Shares of Sera Prognostics, Inc. (NASDAQ:SERA – Get Rating) have been assigned a consensus rating of “Buy” from the six ratings firms that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $19.00.
SERA has been the subject of several research analyst reports. Berenberg Bank initiated coverage on shares of Sera Prognostics in a report on Wednesday, April 27th. They issued a “buy” rating for the company. Citigroup downgraded shares of Sera Prognostics from a “buy” rating to a “neutral” rating in a report on Wednesday, March 30th. Finally, Zacks Investment Research upgraded shares of Sera Prognostics from a “sell” rating to a “hold” rating in a research report on Wednesday.
SERA stock opened at $1.53 on Friday. The company has a market capitalization of $47.28 million and a P/E ratio of -0.35. The company has a 50-day simple moving average of $2.65 and a 200 day simple moving average of $6.08. Sera Prognostics has a fifty-two week low of $1.48 and a fifty-two week high of $15.50. The company has a quick ratio of 15.76, a current ratio of 15.77 and a debt-to-equity ratio of 0.01.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in SERA. Bank of America Corp DE lifted its position in shares of Sera Prognostics by 768.8% in the 4th quarter. Bank of America Corp DE now owns 3,597 shares of the company’s stock valued at $25,000 after acquiring an additional 3,183 shares in the last quarter. American International Group Inc. purchased a new stake in shares of Sera Prognostics in the 3rd quarter valued at approximately $29,000. Deutsche Bank AG purchased a new stake in shares of Sera Prognostics in the 3rd quarter valued at approximately $30,000. Frontier Wealth Management LLC purchased a new stake in shares of Sera Prognostics in the 1st quarter valued at approximately $30,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Sera Prognostics in the 1st quarter valued at approximately $41,000. Institutional investors and hedge funds own 63.20% of the company’s stock.
About Sera Prognostics (Get Rating)
Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies.
- Get a free copy of the StockNews.com research report on Sera Prognostics (SERA)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.